Blue-Ribbon Panel Begins Process Of Closing Up Shop

At an April 1 meeting in Washington, D.C., the Carnegie Commission on Science, Technology, and Government formally began the process of going out of business. The commission's five-year charter ends June 30. The panel was convened in 1988 under the auspices of the Carnegie Corporation of New York to assess the ways in which policymakers take science and technology issues into account when making decisions. The blue-ribbon panel is cochaired by Nobel laureate Joshua Lederberg, former president

Written byBarbara Spector
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The panel was convened in 1988 under the auspices of the Carnegie Corporation of New York to assess the ways in which policymakers take science and technology issues into account when making decisions. The blue-ribbon panel is cochaired by Nobel laureate Joshua Lederberg, former president of Rockefeller University, and William T. Golden, chairman of the board of the American Museum of Natural History in New York, who formerly served as a special consultant on scientific activities to President Harry Truman.

Included among the members of the commission and its advisory council are some of the United States' most prominent scientists, Republican Gerald Ford); three former U.S. senators (Republicans Charles McC. Mathias, Jr. of Maryland and Daniel Evans of Washington, as well as Democrat Lawton Chiles of Florida); three former U.S. representatives (Democrats John Brademas of Indiana and Paul Rogers of Florida, as well as Mathias, who served in the House ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies